Navigation Links
InspireMD Reports Financial Results For Period Ended March 31, 2013
Date:5/8/2013

corded in the same period in 2012. The increase was the result of improved selling activities in key European countries. 

--Gross profit for the March 31, 2013 period increased 49% to $840,000, compared to $564,000 for the March 31, 2012 period. The increase was due to higher revenue and gross margins, which increased from 50% to 55% due to a higher average selling price and lower cost per unit sold.

--Total operating expenses for the March 31, 2013 period were $4.1 million, compared to $3.7 million in the March 31, 2012 period, an increase of $400,000. With enrollment for the MASTER I trial completed, as well as a timing gap between the pre-clinical phase and the start of the recruitment phase of the FDA trial, R&D expenses for the March 31, 2013 period decreased by approximately $500,000, or 33%, compared to the March 31, 2012 period. This decrease was offset by an 81% increase in sales and marketing expenses as we expanded our sales activities worldwide, and a 23% increase in G&A expenses due mainly to an increase in share-based compensation and salary expenses.

--The loss from operations for the March 31, 2013 period was $3.2 million, compared to $3.1 million for the March 31, 2012 period.

--The net loss for the period ended March 31, 2013 totaled $4.9 million, or $0.27 per basic and diluted share, compared to a net loss of $3.1 million, or $0.18 per basic and diluted share in the period ended March 31, 2012. The increased net loss for the quarter just ended resulted primarily from a roughly $400,000 increase in operating expenses, and $1.7 million in financial expenses related to debenture amortization costs and anti-dilution rights expenses. The weighted average number of shares of common stock used in computing net loss per share (basic and diluted) was 18.2 million for the quarter ended March 31, 2013, and 17 million for the quarter ended March 31, 2012.

--At March 31, 2013, cash and cash equivalents was appro
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
2. InspireMD Closes $25 Million Underwritten Public Offering
3. InspireMD Announces Pricing of Underwritten Public Offering of Common Stock and Listing on NYSE MKT
4. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
5. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
6. InspireMD Reports Results for Period Ended Dec. 31, 2012
7. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
8. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
9. InspireMD Reports Results For Period Ending Sept. 30, 2012
10. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
11. InspireMD to Present at Harvard Investors Group on June 27 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- Researchers from the North American Menopause Society (NAMS) found ... too high, 1 putting women at risk for ... close to menopause are commonly told to take supplements ... as osteoporosis, to which they are particularly prone. ... calcium they typically get through their food sources before ...
(Date:7/23/2014)... 2014 This September leading clinicians in orthodontics ... Vegas for DOCtalk 2014 —a "Dynamic ... thinker and private practitioner Dr. David Sarver , ... discuss clinical and practice management efficiency and high quality ... opportunity to welcome fresh thinking and join a community ...
(Date:7/23/2014)... 2014 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... and research facility: Ampio Pharmaceuticals, 373 Inverness ... (720) 437-6500 Michael Macaluso , Ampio,s ... facility will be fully operational this summer, right ... Ampion TM necessary to accommodate the company,s BLA ...
Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 22014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2
... 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: ... a pharmaceutical company dedicated to improving healthcare through ... range of prescription and over-the-counter ("OTC") products, today ... Mr. Tony Liu and Chief Financial Officer, Ms. ...
... that a new market research report is available in ... in China http://www.reportlinker.com/p0363587/The-Top-10-CMOs-in-China.html ... and future outlook of CMO industry in China. It ... the top 10 CMOs. Other leading players are also ...
Cached Medicine Technology:American Oriental Bioengineering's CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintao's Delegation 2Reportlinker Adds The Top 10 CMOs in China 2
(Date:7/23/2014)... Battle Creek, MI (PRWEB) July 23, 2014 ... treatment program that gets clients off to a great ... they can believe in, has launched a new Internet ... , “Many people are surprised to learn that Internet ... sexual addiction or drug addiction, but that it’s trapping ...
(Date:7/23/2014)... Adipic acid is an intermediate chemical ... plastic, often referred to as engineering thermoplastics. These ... the monomers employed. Due to the high production ... increasing number of developing countries, the Asia-Pacific region ... by Europe and North America. Adipic acid in ...
(Date:7/23/2014)... 23, 2014 (HealthDay News) -- Children and teens who lose ... death in adulthood, a new study suggests. People who ... 50 percent greater risk of death during the study period ... parent, according to the report. Although the study found ... risk of premature death, it wasn,t designed to prove cause-and-effect. ...
(Date:7/23/2014)... ill patients arriving at the emergency department, the ... amnesia for rapid, life-saving intubation, despite decades-old studies ... results of a systematic review of 10 recent ... a "wonder drug" are published online in ... of Ketamine on Intracranial and Cerebral Perfusion Pressure ...
(Date:7/23/2014)... 2014 SafeUseNow? , a ... developed by Principled Strategies , today announced ... California . Utilizing SafeUseNow’s patent-pending risk model, Partnership ... misusing and abusing controlled substance drugs, particularly prescription ... its members. , The agreement with Partnership HealthPlan ...
Breaking Medicine News(10 mins):Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2Health News:Ketamine can be a wonder drug for ER patients and their physicians 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 3Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 4
... Bulgaria is to ban the imports of live birds, eggs ... reported suspected bird flu outbreaks. The first case of bird ... province near the Aegean Sea in Western Turkey. Following the ... being slaughtered in order to prevent the spread of the ...
... new study has linked beta-carotene to heart diseases. The ... of deaths in elderly with heart diseases. ,The ... significant after considering other risk factors, according to the ... previous studies that either suggest the carotenoid raises the ...
... novel initiative to combat the spread of childhood obesity, ... of the William J. Clinton Foundation and the American ... a partnership with Nickelodeon's award-winning Let's Just Play pro-social ... a comprehensive media and public awareness campaign, encouraging young ...
... nutritionally good compounds. Lot of research is being done ... herbs, fruits, and vegetables, slowed the growth of prostate ... ,Previous studies already found flavonoids (found in fruits and ... of cancers. ,The current study was intended to ...
... its major 29 hospitals to share information about its ... and interlinking of data would be helpful to citizen ... the case history and treatment provided to this patient. ... with different hospital departments. From a patient's personal information ...
... linked to a number of psychiatric disorders, including ... Early smoking is shown to increase the risk ... disorder, generalized anxiety disorder), and that presence of ... risk for later development of nicotine dependence. ...
Cached Medicine News:Health News:A New Initiative To Fight Childhood Obesity 2Health News:Prostate tumour growth suppressed by flavonoids 2Health News:Delhi Government To Interlink All Major Hospitals Through e-Governance 2Health News:Smokers Are Prone To Number Of Psychiatric Disorders 2
... The Super 66® Stereo Fundus ... magnification viewing of the central retina. Its ... subtle macular and optic disc detail, making ... choroidal neovascular membranes, macular edema, serous detachments ...
The Volk 30D is designed to provide the practitioner a wide field of view with a short working distance. This lens is excellent for use with small pupils....
The 40D is ideal for pediatric ophthalmoscopy and other examinations requiring expansive fundus visibility. Alternatively, this lens may be used at the slit lamp biomicroscope to provide an extremely...
This excellent mid-power lens provides medium field and magnification, with an ideal diameter for grip andmanipulation in the orbital area....
Medicine Products: